Literature DB >> 445419

Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents.

A M Guarino, M Rozencweig, I Kline, J S Penta, J M Venditti, H H Lloyd, D A Holzworth, F M Muggia.   

Abstract

Previous retrospective analyses have suggested a very positive correlation in toxic doses of antineoplastic agents between mice and humans. Additional toxicological information has now been accumulated and reveals a noticeable variability in the existing data base. Nevertheless, it is likely that mouse toxicological studies will become a principal determinant for estimating initial doses to be used in humans. Recognition of the factors responsible for differences in determinations of toxic dose levels in mice will enhance the proper utilization of this approach.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 445419

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Choice of starting dose and escalation for phase I studies of antitumor agents.

Authors:  J S Penta; G L Rosner; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

Authors:  Ferdinand Rombout; Leon Aarons; Mats Karlsson; Anthony Man; France Mentré; Peter Nygren; Amy Racine; Hans Schaefer; Jean-Louis Steimer; Iñaki Troconiz; Achiel van Peer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745

3.  S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.

Authors:  Elena Strekalova; Dmitry Malin; Erin M M Weisenhorn; Jason D Russell; Dominik Hoelper; Aayushi Jain; Joshua J Coon; Peter W Lewis; Vincent L Cryns
Journal:  Breast Cancer Res Treat       Date:  2019-02-02       Impact factor: 4.872

4.  Antitumor drug toxicity in tumor-free and tumor-bearing mice.

Authors:  S D Harrison; H D Giles; E P Denine
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Evaluation of antitumor drug side effects in small animals.

Authors:  W T Bradner; J E Schurig; J B Huftalen; G J Doyle
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma.

Authors:  J M Onoda; K K Nelson; S M Pilarski; N S White; R G Mihu; K V Honn
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

7.  Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.

Authors:  S Fujimoto; M Ogawa
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Adriamycin and daunomycin dose-dependent effects upon contractions of isolated rat myocytes.

Authors:  M C Lowe; J I Smallwood
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.

Authors:  M J McKeage; S E Morgan; F E Boxall; B A Murrer; G C Hard; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.